AstraZeneca (AZN): news on Wednesday 14 October 2026

The 10 stories

Each headline's own score, strongest first. Links go to the publisher.

• +10.0 AstraZeneca Opens $1 Billion R&D Hub, Plans 50% Workforce Growth MyChesCo
  New $1 billion R&D hub and planned workforce growth.
• +9.2 Saudi FDA approves BAXFENDY (baxdrostat) for adults with uncontrolled and resistant hypertension Zawya
  Saudi approval of Baxfendy for hypertension.
• −8.3 AstraZeneca details Phase III HICKORY endpoint miss for efzimfotase alfa in hypophosphatasia AllSci
  Phase III HICKORY trial missed endpoint.
• +7.0 Barclays Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $211.48 Moomoo
  Barclays maintains Buy rating and target.
• +6.7 AstraZeneca completed USD 2 billion deal: analysts target AstraZeneca stock at USD 206.67 - ad-hoc-news.de ad-hoc-news.de
  Completed $2 billion deal with analyst targets above price.
• +6.3 Stockholm stock market opens higher with AstraZeneca leading the way, OMXS30 index up 0.5 percent www.marketscreener.com
  AstraZeneca led Stockholm market higher.
• +5.0 Jefferies keeps GBp 17,500 target for AstraZeneca stock - ad-hoc-news.de ad-hoc-news.de
  Jefferies keeps a high price target.
• +4.2 AstraZeneca’s Pediatric Nexium Study Moves Toward Data Readout, Supporting Long-Term GI Franchise TipRanks
  Pediatric Nexium study progressing toward data readout.
• −1.7 Can AstraZeneca (LSE:AZN) Keep Its Growth Story Intact After A Mixed Run Of Trial Readouts? Kalkine Media
  Questions growth story after mixed trial readouts.
• 0.0 AstraZeneca stock consolidates amid mixed clinical trial results and new oncology partnership Traders Union
  Shares steady amid mixed trials and new partnership.